Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England
- 1 April 2008
- journal article
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 57 (4) , 480-487
- https://doi.org/10.1099/jmm.0.47690-0
Abstract
A 10-year invasive pneumococcal disease (IPD) enhanced surveillance project in the Oxfordshire region of the UK between 1996 and 2005 identified a total of 2691 Streptococcus pneumoniae isolates from all ages that provided a comprehensive description of pneumococcal epidemiology. All isolates were serotyped and those from children under 5 years of age were genotyped and a matched case–control study using adults hospitalized between 1995 and 2000 was performed to estimate the effectiveness of the pneumococcal polysaccharide vaccine in the local population. Fifty-one serotypes were isolated, with different age distributions. The overall incidence of IPD was 9.2 cases per 100 000 population per annum [95 % confidence interval (CI), 8.6–9.9] and that of meningitis was 0.7 per 100 000 population per annum (95 % CI 0.5–0.9). After adjusting for age, serotype 1 was found to be less likely to be associated with meningitis versus other IPD, compared with the most common serotype 14, whereas serotype 12F was more likely to cause meningitis than other IPD. There were significant temporal changes in IPD incidence of four serotypes, with decreases in serotypes 1, 12F and 14 and increases in serotype 8. A possible novel variant (from serotype 6A to 6B) was found using multilocus sequence typing analysis. From the matched case–control study of adults, the pneumococcal polysaccharide vaccine effectiveness was estimated to be 43 % (2–68 %), which did not change significantly after adjustment for pre-existing co-morbidities. The data provide a baseline against which the impact of the pneumococcal conjugate vaccine introduced in the UK in 2006 could be measured.Keywords
This publication has 36 references indexed in Scilit:
- Comparison of secular trends in pneumococcal serotypes causing invasive disease in Denver, Colorado (1971–2004) and serotype coverage by marketed pneumococcal vaccinesClinical Microbiology & Infection, 2006
- Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control studyThe Lancet, 2006
- Capsular Serotype–Specific Attack Rates and Duration of Carriage ofStreptococcuspneumoniaein a Population of ChildrenThe Journal of Infectious Diseases, 2006
- Pneumococcal polysaccharide vaccine uptake in England, 1989–2003, prior to the introduction of a vaccination programme for older adultsJournal of Public Health, 2006
- Identification of Invasive Serotype 1 Pneumococcal Isolates That Express Nonhemolytic PneumolysinJournal of Clinical Microbiology, 2006
- Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialThe Lancet, 2005
- Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adultsVaccine, 2004
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionNew England Journal of Medicine, 2003
- An Outbreak of Streptococcus pneumoniae Serotype 1 in a Closed Community in Southern IsraelClinical Infectious Diseases, 2000
- An Epidemic of Pneumococcal Disease in an Overcrowded, Inadequately Ventilated JailNew England Journal of Medicine, 1994